NASDAQ: ILMN

Illumina Accelerator Invests in Seven Omics Startups Advancing Breakthrough Therapeutics, Diagnostics, DNA Storage, Mental Wellness, and Sustainable Foods Applications

Summary: 

Illumina Accelerator portfolio grows to 68 startups

93% of graduate companies successfully secured additional capital

Press Release

Illumina Accelerator portfolio grows to 68 startups

93% of graduate companies successfully secured additional capital

Illumina Unveils Groundbreaking Comprehensive Genomic Profiling Test for Cancer in Europe

The single in vitro diagnostic test helps inform therapy decisions according to clinical guidelines to enable precision medicine earlier in the disease journey
Press Release

SAN DIEGO, March 16, 2022 /3BL Media/ -- Illumina, Inc. (NASDAQ:ILMN) announced the launch of TruSight™ Oncology (TSO) Comprehensive (EU), a single test that assesses multiple tumor genes and biomarkers to reveal the specific molecular profile of a patient's cancer. With its global launch first taking place in Europe, the in vitro diagnostic (IVD) kit will help inform precision medicine decisions for cancer patients across the continent.

Illumina and Trivitron Partner to Accelerate Disease Detection and Diagnosis for Patients in India

Partnership will expand use of next-generation sequencing (NGS) to help diagnose patients quickly and more accurately.
Press Release

NEW DELHI, March 15, 2022 /3BL Media/ - Illumina Singapore, subsidiary of Illumina Inc (NASDAQ: ILMN) and Trivitron Healthcare, one of India's largest medical technology companies, have entered into a strategic partnership to develop and expand the use of next-generation sequencing (NGS)-based in-vitro diagnostic tests (IVD) in India.

Illumina Celebrates Shannon Whitmore: A Real Time Revolutionary and Scientific Computing Innovator

Multimedia with summary

Shannon Whitmore is a Real Time Revolutionary who has been driving the field of scientific computing ever since developing a tool for visualizing the secondary structure of rRNA for her master's thesis.

Illumina Named One of Fast Company's Most Innovative Companies for 2022

Illumina honored for developing several innovative technologies, including COVID-19 sequencing tests to track the spread of variants even at smaller labs
Multimedia with summary

We are honored to have been named one of Fast Company’s Most Innovative Companies for 2022.

A few of our innovative technologies and advancements in 2021 included:

Illumina's Technology Supports Biodiversity and Conservation Initiatives

Illumina Celebrates World Wildlife Day
Multimedia with summary

Illumina’s innovations transcend beyond improving the health of humans to improving the health of all living things. Our technology is being used to support the biodiversity of our planet in numerous ways, including:

Celebrating Women's History Month: Illumina Spotlights Scientist Geraldine Pittman Woods

Multimedia with summary

Geraldine Pittman Woods was a neuroembryologist who dedicated much of her life to expanding opportunities for people of color in STEM and education. Here is a small piece of her story.

She briefly became a professor at Howard University after completing her PhD, but like many women of the time, Geraldine retired from her field when she married. However, she never stopped working.

She is remembered for saying, “You are never too busy to do community service.”

Illumina Celebrates Rare Disease Day

Recognizing and supporting rare disease organizations and families around the world
Multimedia with summary

On February 28th, and everyday, Illumina recognizes Rare Disease Day 2022. Throughout the entire month of February, we highlighted various organizations that support and advocate for patients and families impacted by rare genetic disorders.

Growing Grassroots Support for the Rare Disease Community in Romania

NoRo pilots the country’s first and only patient-run reference center for rare diseases
Article

In 2007, Dorica Dan, the mother of a child with the rare disease Prader Willi Syndrome, envisioned the first and only patient-run reference center for rare diseases in Europe. It would help patients and families with the decisions and therapies that are needed after receiving their diagnosis.

Pages

Subscribe to NASDAQ: ILMN